Oxycodone Actavis (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodone Actavis, is an opioid analgesic presented as a strength/form for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Oxycodone Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Actavis is an opioid analgesic that acts on the central nervous system to manage pain. - Acute postoperative pain: Provides effective relief following surgical procedures. - Cancer‑related pain: Helps control moderate to severe pain associated with malignancies. - Chronic non‑cancer pain: Used when long‑term pain requires strong opioid therapy.

Adverse reactions to oxycodone can vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea and vomiting: Frequent gastrointestinal upset. - Constipation: Reduced bowel motility leading to hard stools. - Drowsiness or sedation: Increased sleepiness or reduced alertness. - Dizziness: Light‑headed sensations, especially when standing. - Dry mouth: Reduced salivation causing oral discomfort. - Sweating: Excessive perspiration without exertion.

Serious or Rare Side Effects: - Respiratory depression: Slowed or shallow breathing that can be life‑threatening. - Severe hypotension: Marked drop in blood pressure. - Seizures: Uncontrolled electrical activity in the brain. - Allergic reactions: Rash, itching, swelling, or anaphylaxis. - Dependence or addiction: Potential for misuse and physical dependence. - Adrenal insufficiency: Rare hormonal imbalance affecting stress response.

When prescribing oxycodone, clinicians should consider several safety factors to minimize risk. - Assess pain severity and prior opioid use: Determine if opioid therapy is appropriate. - Evaluate respiratory function: Monitor for signs of respiratory depression, especially in opioid‑naïve patients. - Review concomitant medications: Identify drugs that may increase sedation or respiratory risk. - Monitor for signs of dependence: Watch for behavioral changes indicating misuse. - Adjust dose in renal or hepatic impairment: Use lower doses and titrate cautiously. - Store below 25°C: Keep in the original container, protect from moisture and direct sunlight.

Oxycodone may interact with a range of medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): Heightened risk of respiratory depression and profound sedation. - MAO inhibitors (e.g., phenelzine, selegiline): Can cause severe hypertension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): Increase oxy‑hydroxy‑oxycodone plasma levels, raising overdose risk.

Moderate Interactions (Monitor Closely): - CNS stimulants (e.g., cocaine, amphetamines): May counteract opioid sedation, leading to unpredictable effects. - Antidepressants (e.g., SSRIs, SNRIs): Potential for serotonin syndrome when combined with other serotonergic agents. - Diuretics: May enhance hypotensive effects, requiring blood pressure monitoring.